THE GLOBAL REGENERATIVE MEDICINE MARKET SIZE WAS VALUED AT USD 4.68 BILLION IN 2020 AND IS EXPECTED TO REACH USD 27.08 BILLION BY 2026, AT A CAGR OF 34% DURING 2021-2026

Regenerative Medicine Market Size and Share & Trends Analysis Report by Application (Oncology, Genetic Disorders, Dermatology, Musculoskeletal, and Other), Product Type (Gene Therapies, Cell Therapies, and Tissue-Engineered), End-Users (Hospitals, Cancer Care Centers, Wound Care Centers, Ambulatory Surgical Centers, and Other End-Users), Geography (North America, Europe, APAC, Latin America, and Middle East & Africa) Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2021–2026.

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

284 Pages

84 Tables

159 Charts

5 Regions

18 Countries

39 Companies

4 Market Segment

REGENERATIVE MEDICINE MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (REVENUE) USD 27.08 BILLION (2026)
CAGR 34% (2021–2026)
Base Year 2020
Forecast Year 2021–2026
Market Segments Application (Oncology, Genetic Disorders, Dermatology, Musculoskeletal, and Other), Product Type (Gene Therapies, Cell Therapies, and Tissue-Engineered), End-users (Hospitals, Cancer Care Centers, Wound Care Centers, Ambulatory Surgical Centers, and Others)
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa
Countries Covered US, Canada, Germany, France, UK, Italy, Spain, Japan, China, Australia, South Korea, India, Brazil, Mexico, Turkey, Saudi Arabia, South Africa, and UAE

REGENERATIVE MEDICINE INDUSTRY INSIGHTS

The global regenerative medicine market size was valued at USD 4.68 billion in 2020 and is estimated to reach USD 27.08 billion by 2026, growing at a cumulative average growth rate (CAGR) of 30% during the forecast period. The increasing prevalence of cancer and genetic disorders is popularizing the regenerative medicine trends across the globe.

Increased R&D investments by pharmaceutical companies will drive the demand for regenerative medicines. Europe plays a significant role in supporting the development and authorization of these products for several genetic and rare disorders. Increased funding via several venture capitalists and governments, and private institutions contribute significantly to the global regenerative medicine market growth.

The increased prevalence of diseases such as cardiovascular diseases and diabetes can drive cell and gene therapy and tissue-engineered products. With the rise in thermal burns, occupational burn accidents, and chronic wounds, regenerative medicine products will experience steady growth. Novartis and Gilead Sciences are the key companies offering various therapies to treat cancer, genetic, and rare disorders.  

SNIPPETS

  • Cell and gene therapy is rapidly emerging as the most promising part of regenerative medicines.
  • Mergers and Acquisitions are the latest trends in the industry. The key vendors are acquiring the existing highly successful cell and gene therapy companies with huge amounts.
  • The overall merger and acquisition activities are worth up to USD 33 billion in the regenerative medicine industry.
  • South Korea is one of the leading regions in APAC, with significant innovation and development in cell-based therapy, specifically using stem cell therapies.
  • The European Union focuses on the largest innovation and research program with USD95 billion funding over seven years from 2007–2020.

REGENERATIVE MEDICINE INDUSTRY OPPORTUNITIES AND GROWTH FACTORS

  • A strong pipeline portfolio by numerous companies will boost the market growth.
  • The faster regulatory approvals for the cell and gene therapy products, especially from the US and European regulatory authorities, provide huge opportunities to penetrate the market faster.
  • Rapid product developments and innovative product launch in the industry every year with smooth and favourable approvals is boosting the opportunities in the industry.

REGENERATIVE MEDICINE MARKET SEGMENTATION

This research report includes a detailed segmentation by

  • Application
  • Products
  • End-users
  • Geography

INSIGHTS BY APPLICATION

The oncology segment expects to occupy absolute growth of over USD 14 billion by 2026

Oncology constitutes the largest portion of the global regenerative medicine market share. The development of curative therapies by CAR-T and cell and gene therapies is widely popularized in the oncology therapeutic area. The increasing global prevalence rates and the increasing rates of different types of life-threatening cancers are the most important key factors that drive the oncology segment.

The genetic disorder segment will witness an incremental growth of over USD 8 billion by 2026. The rapid increase in genetic and serious life-threatening rare disorders is one of the important factors that drive the market. In addition, the increasing burden of genetic diseases is growing across the globe, thereby influencing industry growth.

INSIGHTS BY PRODUCT

The gene therapy segment is anticipated to retain market dominance during the forecast period.

Consistent innovations in gene therapies due to the increased number of clinical trials and pipeline products are driving the growth prospects. Hence, the increased inflow of funding for the development of gene therapy is one of the driving factors for the sector growth Cell therapy is the major revenue contributor. The increasing prevalence of diabetes and foot ulcers is the primary factor contributing to the growth of tissue-engineered products. The tissue-engineered product segment to grow at a CAGR of 8% by 2026.

Increased funding from government bodies and venture capitalists leads to the development of advanced and innovative cell therapies. The rising awareness and expansion of reimbursement schemes in the emerging market will generate lucrative growth opportunities for cell therapy products.

INSIGHTS BY END-USERS

Hospitals are the fastest-growing end-user segment.

Hospitals are likely to remain a dominant revenue contributor to the global regenerative medicine market. Around 50% of therapeutic surgeries performed in the US annually, including cardiovascular and musculoskeletal, occur in hospitals. Cancer care centers are likely to witness an incremental growth of approx. USD 10 billion by 2026. As cancer is the second leading cause of death across the globe, which is responsible for approx. 10 million deaths annually, the scope of cancer centers is growing. Key vendors are focusing more on cancer care centers than hospitals to promote their products. As the cancer centers are being covered under reimbursement schemes, the growth of these facilities is likely to increase during the forecast period.

INSIGHTS BY GEOGRAPHY

In North America, the acceptance of regenerative medicine is relatively higher than in other developed countries.  North America to accounts for the largest market share of the global regenerative medicine market. The growth can be primarily attributed to the increasing population with different types of cancers such as non-Hodgkin lymphoma, Hodgkin lymphoma, melanoma of the skin, and leukaemia in the North American region.  Furthermore, North America consists of the highest number of regenerative medicine companies, which is adding to the market growth in the region. Europe has highly developed manufacturing facilities, which is driving the market growth in the European region. Most vendors in Europe depend on external sources for expansion and R&D activities.

COMPETITIVE LANDSCAPE

Amgen, Bristol Myers Squibb, Dendreon, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Osiris, Organogenesis, and Vericel are the key vendors in the global regenerative medicine market. Global key players dominate the market shares due to wide distribution networks, innovative product launches, and broad product offerings. Companies are focusing on product innovations and strengthening their distribution channel to expand market presence globally. The market has developed innovative therapies in the field. For instance, Bristol Myers Squibb received approval from the US FDA for its product – Lisocel - to treat relapsed/refractory diffuse large-B cell lymphoma (DLBCL) in February 2021. Small players are collaborating with prominent players to gain a competitive advantage in the market.

The global regenerative medicine market research report includes in-depth coverage of industry analysis with revenue and forecast insights for the following segments:

Segmentation by Application

  • Oncology
  • Genetic Disorders
  • Dermatology
  • Musculoskeletal
  • Others

Segmentation by Product

  • Gene Therapies
  • Cell Therapies
  • Tissue-Engineered Therapies

Segmentation by End-Users

  • Hospitals
  • Cancer Care Centers
  • Wound Care Centers
  • ASCs
  • Others

Segmentation by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • Japan
    • China
    • Australia
    • South Korea
    • India
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • South Africa
    • UAE

Frequently Asked Questions

Global Regenerative medicine market size is to likely to reach USD 27 billion by 2026, growing at a CAGR of over 30% during the forecast period.
Oncology, genetic disorders, and musculoskeletal disorders are the critical applications of the product.
Amgen, Bristol Myers Squibb, Dendreon, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Osiris, Organogenesis, and Vericel are the major vendors in the market.
The gene therapy segment is likely to account for the largest industry share.
North America is likely to hold the largest share by 2026.
The covid pandemic disrupted the supply chain of raw materials required to commercialize gene cell therapy and tissue-engineered products.
Download Free Sample
Read More

Select a license type that suits your business needs

Single User Licence
$3750.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5 User Licence
$4250.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
$5250.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Select a license type that suits your business needs

Best Value Tag
Coming Soon
  • Stay tuned with us.

YOU CAN GET A FREE SAMPLE OF THIS REPORT!

Fill out your details & get your free sample

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Our Clients

Licence Types What are these?

Our Clients Speak

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date